Pfizer (PFE)
(Delayed Data from NYSE)
$29.97 USD
+0.26 (0.88%)
Updated Jul 19, 2024 04:02 PM ET
After-Market: $29.98 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PFE 29.97 +0.26(0.88%)
Will PFE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Other News for PFE
Kamala Harris' potential impact on health care stocks
Ex-Dividend Date Nearing for These 10 Stocks – Week of July 22, 2024
Here are Big Pharma’s leading blockbuster makers
Dividend Champion, Contender, And Challenger Highlights: Week Of July 21
See Which Of The Latest 13F Filers Holds Pfizer